Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204340) titled 'TLN-372 in Advanced KRAS Mutant Solid Tumors' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Treeline Biosciences, Inc.
Condition:
KRAS Mutant Solid Tumors
Intervention:
Drug: TLN-372
Drug: TLN-372 in combination with cetuximab
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 9, 2025
Target Sample Size: 240
Countries of Recruitment:
United States
Australia
United States
To know more, visit https://clinicaltrials.gov/study/...